Dr. Diaz on Pembrolizumab for CRC

Luis A. Diaz, MD
Published: Monday, Jun 19, 2017



Luis A. Diaz, MD, head of the division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center, discusses the impact of pembrolizumab (Keytruda) in patients with colorectal cancer (CRC).

In KEYNOTE-016, only 12 patients with CRC were reported, and it achieved a breakthrough therapy designation status by the FDA, explains Diaz. This led to pembrolizumab being investigated throughout multiple tumor types and it has demonstrated potent efficacy throughout.

Overall, patients with CRC being treated with pembrolizumab are experiencing a benefit, states Diaz.
 
SELECTED
LANGUAGE


Luis A. Diaz, MD, head of the division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center, discusses the impact of pembrolizumab (Keytruda) in patients with colorectal cancer (CRC).

In KEYNOTE-016, only 12 patients with CRC were reported, and it achieved a breakthrough therapy designation status by the FDA, explains Diaz. This led to pembrolizumab being investigated throughout multiple tumor types and it has demonstrated potent efficacy throughout.

Overall, patients with CRC being treated with pembrolizumab are experiencing a benefit, states Diaz.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How to Use Liquid Biopsies Throughout the Lung Cancer Treatment Continuum OnlineJan 31, 20191.5
Community Practice Connections™: Current Status and the Future Potential of CAR T-Cell Therapy for Lymphoid Malignancies: The Experts Weigh-In on Recent Data and Clinical ExperienceJan 31, 20192.0
Publication Bottom Border
Border Publication
x